Nuvectis Pharma reports Q3 2026 net loss of $30.1M, completes NXP100/NXP200 in-licensing

Nuvectis Pharma reported a Q3 2026 net loss of $30.1 million, or $1.02 per share, with cash and equivalents of $140.7 million. The company completed an in-licensing agreement for ex-China rights to ciprocopan (NXP100) and NXP200 from Haisco Pharmaceutical Group, and reported Phase 1b response rates of 40.0% and 42.9% in high-grade and low-grade glioma patients for NXP200.

Detected & updated continuously · Source: Nebula